Korea Exchange · Healthcare
Celltrion stock from India: price, numbers and tax
Celltrion (068270) is not currently available to trade on Paasa; this guide covers the price, the numbers and the Indian tax treatment.
By Paasa · Updated
Celltrion at a glance
- Price
- ₩179,600.00-₩3,900.00 (2.13%)
- Market cap
- ₩41.19T
- Day range
- ₩179,500.00 – ₩182,300.00
- P/E
- 25.92
- Dividend yield
- 0.40%
- Volume
- 582.43K
- 1 month
- -1.91%
- 6 months
- -11.09%
- YTD
- +4.19%
- 1 year
- +7.51%
- 5 years
- -2.48%
Celltrion statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | ₩4.2T | ₩3.6T | ₩2.2T | ₩2.3T | ₩1.9T |
| Gross profit | ₩2.4T | ₩1.7T | ₩1.0T | ₩1.0T | ₩1.1T |
| Operating income | ₩1.2T | ₩492.0B | ₩651.5B | ₩647.2B | ₩744.2B |
| Net income | ₩1.0T | ₩422.7B | ₩535.6B | ₩537.8B | ₩579.5B |
| Earnings per share | ₩4,466.05 | ₩1,969.23 | ₩3,442.31 | ₩3,894.00 | ₩3,663.00 |
| EBITDA | ₩1.5T | ₩1.1T | ₩937.8B | ₩853.0B | ₩958.3B |
| Total assets | ₩22.3T | ₩21.1T | ₩19.9T | ₩5.9T | ₩5.7T |
| Total debt | ₩3.7T | ₩2.2T | ₩1.9T | ₩792.3B | ₩744.4B |
| Cash and short-term investments | ₩1.2T | ₩1.1T | ₩757.5B | ₩594.5B | ₩1.2T |
| Shareholders' equity | ₩17.2T | ₩17.4T | ₩17.0T | ₩4.1T | ₩3.9T |
| Operating cash flow | ₩586.5B | ₩901.9B | ₩537.2B | ₩863.5M | ₩911.2B |
| Free cash flow | ₩478.2B | ₩568.3B | ₩183.4B | −₩311.1B | ₩589.6B |
| Capital expenditure | −₩108.2B | −₩333.5B | −₩353.7B | −₩312.0B | −₩321.6B |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in KRW; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| Prestige BioPharma | 950210.KS | ₩5,960.00 | ₩358.17B |
| Amgen | AMGN | $407.44 | $219.90B |
| Genmab | GMAB.CO | $2,356.00 | $144.64B |
| RemeGen | 688331.SS | CNH 111.21 | CNH 61.54B |
| argenx | ARGX.BR | $705.60 | $43.88B |
| UCB | UCB.BR | $201.80 | $38.43B |
| Shanghai Junshi Biosciences | 688180.SS | CNH 33.42 | CNH 34.03B |
| Biogen | BIIB | $218.43 | $32.27B |
Peers as grouped by the data provider. This is not an investment recommendation.
Why invest in Celltrion from India
What Celltrion does
Celltrion, Inc., a South Korean biopharmaceutical company, specializes in the development and manufacturing of protein-based therapies, including treatments for oncology. Its commercial portfolio features established products such as Remsima, Truxima, and Herzuma, alongside a range of generic pharmaceuticals and diagnostic kits for COVID-19. Celltrion operates in the Biotechnology industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
What tax do I pay in India when I sell Celltrion shares?
In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the KRW/INR rate on the day you bought and the day you sold, so the currency move is part of the gain.